McKesson Corporation Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by McKesson Corporation on June 9, 2026. The report details a material definitive agreement entered into by certain subsidiaries, including McKesson Medical-Surgical Top Holdings, Inc., regarding the amendment of an existing credit facility.
Key Financial Metrics and Debt Structure
The filing announces the creation of a new senior secured term "B" loan facility with the following terms:
- Facility Amount: $2,250.0 million.
- Maturity Date: 2032.
- Interest Rate Structure: Borrower's option between (i) Adjusted Term SOFR Rate plus 2.25% per annum, or (ii) Base Rate plus 1.25% per annum.
- Initial Rate Selection: Adjusted Term SOFR Rate plus 2.25% per annum.
- Collateral: Secured by a security interest in substantially all tangible and intangible assets of the Borrower and certain material U.S. subsidiaries.
The filing text does not provide specific values for revenue, profit, cash flow, margins, or overall liquidity positions outside of the terms of this specific debt instrument.
Material Changes and Covenants
The amendment modifies the Credit Agreement dated April 1, 2026, to include the new Term B Loan Facility. All other terms of the Credit Agreement remain substantially the same. The Borrower is subject to the following financial covenants:
- Maximum total net leverage ratio covenant.
- Minimum interest coverage ratio covenant.
Customary cure rights apply to these covenants.
Outlook, Risks, and Contingencies
The filing notes that participants in the Credit Agreement and their affiliates may engage in various commercial transactions (banking, derivatives, advisory, etc.) with the Company for which they receive customary fees. The description of the facility is qualified by reference to the executed Amendment filed as Exhibit 10.1.
Key Facts for Investor Verification
- Verify the impact of the new $2.25 billion debt obligation on the company's total net leverage ratio and interest coverage ratio.
- Review the full text of Amendment No. 1 to the Credit Agreement (Exhibit 10.1) for specific definitions of "Excluded Assets" and cure rights.
- Confirm the purpose of the new Term B Loan Facility (e.g., refinancing, capital expenditure, or general corporate purposes) as it is not explicitly detailed in the summary text.
- Monitor future interest rate fluctuations given the initial selection of a floating rate based on Adjusted Term SOFR.